An Extension Study of JR-171-101 Study in Patients With MPS I

Status Active, not recruiting

Clinical Trial Summary

Phase I/II, open label, multicenter, multinational (Japan, Brazil and the US) extension study of JR-171-101 for the treatment of MPS I

Clinical Trial Description

Patients who have completed the Part2 of JR-171-101 study and fulfill all eligibility criteria can be enrolled in this JR-171-102 study. Until the dose determination in the JR-171-102 study, subjects will intravenously receive either low dose or high dose of JR-171 at the same doses received at Week 12 of the JR-171-101 study. Thereafter, all subjects will be transitioned to the optimal dose determined based on the results of JR-171-101 study. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04453085
Study type	Interventional
Source	JCR Pharmaceuticals Co., Ltd.
Contact
Status	Active, not recruiting
Phase	Phase 1/Phase 2
Start date	October 28, 2021
Completion date	April 30, 2025

View Details

See also
Status	Clinical Trial	Phase
Terminated	`NCT01675674` - Study to Detect Unrecognized Mucopolysaccharidosis in Children Visiting Rheumatology, Hand or Skeletal Dysplasia Clinics	N/A
Completed	`NCT00741338` - Immune Tolerance Study With Aldurazyme® (Laronidase)	Phase 1/Phase 2
Recruiting	`NCT05687474` - Baby Detect : Genomic Newborn Screening
Completed	`NCT04227600` - A Study of JR-171 in Patients With Mucopolysaccharidosis I	Phase 1/Phase 2
Completed	`NCT05134571` - China Post-marketing Surveillance (PMS) Study of Aldurazyme®	Phase 4
Terminated	`NCT00418821` - A Study of the Effect of Aldurazyme® (Laronidase) Treatment on Lactation in Female Patients With Mucopolysaccharidosis I (MPS I) and Their Breastfed Infants	Phase 4
Completed	`NCT03071341` - Extension Study Evaluating Long Term Safety and Activity of AGT-181 in Children With MPS I	Phase 1/Phase 2
Completed	`NCT03053089` - Safety and Dose Ranging Study of Human Insulin Receptor MAb-IDUA Fusion Protein in Adults and Children With MPS I	Phase 1/Phase 2
Completed	`NCT00146757` - A Study Evaluating the Safety and Pharmacokinetics of Aldurazyme® (Laronidase) in MPS I Patients Less Than 5 Years Old	Phase 2
Active, not recruiting	`NCT04628871` - Long Term Follow-up (LTFU) of Subjects Who Received SB-318, SB-913, or SB-FIX
Completed	`NCT02597114` - Extension Study of AGT-181-102 to Evaluate Long Term Safety and Activity of AGT-181	Phase 1
Terminated	`NCT00748969` - Clinical Trial of Growth Hormone in MPS I, II, and VI	Phase 2/Phase 3
Terminated	`NCT00215527` - Intrathecal Enzyme Replacement Therapy for Spinal Cord Compression in Mucopolysaccharidosis (MPS) I	Phase 1
Recruiting	`NCT05619900` - Registry of Patients Diagnosed With Lysosomal Storage Diseases
Completed	`NCT00146770` - Phase 3 Extension Study of the Safety and Efficacy of Aldurazyme® (Laronidase) in Mucopolysaccharidosis I (MPS I) Patients	Phase 3
Completed	`NCT00176917` - Stem Cell Transplantation for Hurler	Phase 2
Completed	`NCT00176891` - Stem Cell Transplant w/Laronidase for Hurler	Phase 2
Active, not recruiting	`NCT03153319` - Study to Evaluate the Safety and Efficacy of Adalimumab in MPS I, II, and VI	Phase 1/Phase 2
Completed	`NCT00852358` - A Study of Intrathecal Enzyme Therapy for Cognitive Decline in MPS I	N/A
Enrolling by invitation	`NCT06103487` - Long Term Follow-Up for RGX-111